SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is trending as market participants keenly debate the impact of escalating military operations in the Middle East, with sentiment sharply divided between expectations of a significant downturn and beliefs in a swift "buy the dip" recovery. Traders are particularly focused on potential spikes in oil prices and their inflationary consequences, while many also scrutinize the relatively muted initial market reaction amidst the broader geopolitical uncertainty.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating geopolitical tensions in the Middle East and reports of the Strait of Hormuz's effective closure drive expectations of surging oil prices. The community anticipates a significant short squeeze, drawing comparisons to its previous parabolic surge during similar global conflicts, though concerns about potential dilution are also present.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating geopolitical tensions in the Middle East, including reports of US-Israeli strikes and Iranian retaliation, create widespread concern about disruptions to crucial oil shipping lanes like the Strait of Hormuz. The community is actively debating whether a significant oil price surge is imminent due to a real supply shock or if diplomatic efforts will quickly de-escalate the situation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as community sentiment is sharply divided over the escalating Middle East conflict, with some anticipating a significant market correction due to rising oil prices and geopolitical uncertainty, while others expect a swift rebound following reports of key Iranian leadership casualties and potential de-escalation talks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to fierce community debate surrounding reported US and Israeli military operations in Iran, with proponents lauding it as a strong strategic move by Donald Trump, while detractors criticize it as a potentially destabilizing distraction from other pressing issues.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending due to rapidly escalating Middle East tensions, including reported attacks on oil tankers and fears of Strait of Hormuz disruptions, leading the community to widely anticipate a significant oil price surge and a major rotation of capital into energy assets.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending amidst intense community discussion about escalating Middle East tensions, with many anticipating that potential conflict and disruptions to the Strait of Hormuz could trigger significant oil price spikes and position XOM as a critical hedge.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as escalating Middle East tensions fuel fears of oil supply disruptions and a potential surge in crude prices, with the community actively discussing the company's strong position to benefit from these geopolitical shifts and its expanded operations in Venezuela.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

Raytheon Technologies is trending as escalating global geopolitical tensions and robust U.S. defense spending proposals drive a bullish sentiment, with the community actively discussing its critical role in missile systems and substantial contract backlog.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp (BATL) is trending as escalating geopolitical tensions in the Middle East drive community discussion around a potential oil price surge and a massive short squeeze. Traders are actively weighing the recent strategic asset sale that significantly reduced debt against the backdrop of potential disruptions to vital shipping routes and the broader impact on energy markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research

Zacks Research upgraded shares of MoonLake Immunotherapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.97) earnings per share (EPS) for the quarter, meeting the...

Lifesci Capital Has Optimistic Outlook of MLTX Q4 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at Lifesci Capital raised their Q4 2025 EPS estimates for shares of MoonLake Immunotherapeutics in a report released on...

Needham & Company LLC Issues Positive Forecast for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price

Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $30.00

BTIG Research increased their price objective on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a "buy" rating in a report on Monday...

MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins

MoonLake Immunotherapeutics (NASDAQ:MLTX) used its Investor Day presentation to outline updates across its clinical portfolio for sonelokimab (SLK), a tri-specific nanobody designed to inhibit IL-17A...

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets Stock futures slumped after Trump's weekend tariff tantrum added uncertainty to American trade policy and was another blow to bullish...

<ul class="summary-bullets"><li>President Donald Trump announced over the weekend that global tariffs would rise from 10% to 15%.&nbsp;</li><li>Traders are also watching last-ditch nuclear negotiations with Iran scheduled in Geneva later this week.&nbsp;</li><li>Nvidia earnings later this week could define the next leg of the market.</li></ul>U.S. stock futures were sharply lower early Monday as investors grappled with a renewed tariff uncertainty, rising geopolitical tensions with Iran, and awaited Nvidia's big earnings report later this week. Last week’s momentum is being tested by President Donald Trump’s announcement over the weekend of a hike in global tariffs from 10% to 15%, which came a day after the Supreme Court struck it down as ‘anti-American.’The markets are also watching last-ditch nuclear talk attempts with Iran in Geneva this Thursday, amidst reports that the U.S. is considering significant military action if diplomacy fails.&nbsp;As of 3:00 a.m. ET on Monday, Nasdaq futures fell 0.6%, the S&amp;P 500 and Dow futures declined 0.5%, while Russell 2000 futures were down nearly 1%.Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved to ‘bearish’ from ‘neutral’ last week, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bearish’ amid high message volumes.&nbsp;On the other hand, precious metals have seen a breakout, with gold rising above $5,100 and silver nearing $88/oz.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chip giant reports earnings on Feb 25. Beyond its guidance, all eyes will be on its commentary on AI hype, investments, and sustainability.Netflix (NFLX):&nbsp;The stock is facing potential downward pressure after President Trump threatened consequences if board member Susan Rice is not removed. This adds another layer of uncertainty as it pursues its bid for Paramount Skydance (PSKY).&nbsp;Honeywell (HON):&nbsp;It has entered into an amended deal to acquire Johnson Matthey’s Catalyst Technologies business for $1.8 billion.Vanda Pharmaceuticals (VNDA):&nbsp;The US FDA has approved Bysanti for bipolar I disorder and schizophrenia.Moonlake Immunotherapeutics (MLTX):&nbsp;Positive Phase 2 data for its spinal disease drug have led to strong after-hours gains. Traders will be watching this stock closely as we head into a new week.&nbsp;Immunity Bio (IBRX):&nbsp;This biotech stock continues to garner retail attention. Executive chairman Patrick Soon-Shiong&nbsp;<a href="http://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us">teased</a> a detailed three-year expansion roadmap, with a detailed press release expected on Monday.&nbsp;Deere &amp; Co (DE):&nbsp;One of the most actively traded stocks last week saw a downgrade to ‘Underperform’ from Jefferies, with a target price of $550. The analyst believes it is already ‘discounted a full recovery’ and trades at steep valuations.&nbsp;Rolls-Royce (RYCEY): The company is reportedly preparing a buyback program of up to €1.5 billion.Other tickers trending on Stocktwits at the time of writing included Capricor Therapeutics (CAPR), Kraft Heinz Co (KHC), Oklo Inc (OKLO), and Ardelyx (ARDX), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will be monitoring the release of factory orders at 10:00 am ET. They will also be watching for commentary from Fed Governor Christopher Wallace before the bell today.&nbsp;On the earnings radar, investors will be watching for the quarterly reports from Domino’s Pizza (DPZ), GeneDX (WGS), Freshpet (FRPT), and Dominion Energy (D), among others, before the bell&nbsp;today. Also watch out for Hims &amp; Hers (HIMS), Keysite Technologies (KEYS), and Diamonback Energy (FANG) that report after market close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 

Equity

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 


<ul class="summary-bullets"><li>Phase 2 S-OLARIS trial data showed 81% of patients improved within 12 weeks, meeting the primary endpoint.</li><li>Imaging and biomarker results confirming reduced spine inflammation, while no new safety issues were identified.</li><li>MoonLake enters Investor Day with funding in place into the second half of 2027, supported by $394 million in cash.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. (MLTX) surged over 10% in overnight trading on Sunday ahead of Monday’s Investor Day, as newly released clinical data for its experimental spine disease drug reignited investor interest after a volatile year marked by a major setback.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> jumped over 3% on Friday to hit $18.77, but ended 0.3% lower in after-hours trading.&nbsp;<h2 class="st-heading-2">Phase 2 Trial In Spine Disease Meets Primary Endpoint&nbsp;</h2>On Sunday, the company reported positive topline results from a Phase 2 clinical trial of Sonelokimab (SLK) in patients with axial spondyloarthritis, a chronic inflammatory disease that causes severe back pain, stiffness, and progressive loss of mobility.&nbsp;MoonLake said its Phase 2 S-OLARIS trial showed that 81% of patients treated with SLK saw clear improvement in their condition within 12 weeks. The trial met its primary endpoint, using the same standard doctors and regulators rely on to judge whether new treatments for this disease reduce pain, inflammation, and limits on daily movement.MoonLake reported that more than 80% of patients also showed clinically important improvement on additional disease activity measures by Week 12. These clinical gains were supported by imaging results, with MRI scans showing reductions in inflammation inside affected joints.PET imaging further showed a reduction in both inflammation and osteoblast activity within the sacroiliac joints by Week 12. Osteoblast activity is a key driver of irreversible bone formation and progressive loss of mobility in axial spondyloarthritis. Tests on patients’ blood and tissue showed that the drug quickly and consistently reduced the inflammation signals that drive the disease to worsen over time.The company said the safety profile of SLK in the S-OLARIS trial was consistent with previous studies and that no new safety signals were identified.&nbsp;<h2 class="st-heading-2">Cash Position Extends Runway Into 2027</h2>MoonLake reported that it ended 2025 with $394 million in cash, cash equivalents, and short-term marketable securities. The company said this, combined with proceeds from a recent $75 million equity raise, is expected to fund operations into the second half of 2027.The company also announced an amended debt facility with Hercules Capital, including a $25 million drawdown and up to $400 million in additional non-dilutive funding available to support future needs.<h2 class="st-heading-2">Why The Data Matters&nbsp;</h2>The Phase 2 readout marks a positive development for MoonLake following a sharp selloff in September 2025, when one of its Phase 3 trials in a separate skin disease indication failed to meet its primary endpoint. That result triggered a roughly 90% collapse in the stock price over two sessions and sparked a securities class-action lawsuit filed in December.MoonLake will host its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-heads-into-investor-day-with-fda-momentum/cZRjp7xR4wl">Investor Day</a> on Feb. 23, with presentations from its CEO, chief scientific officer, and CFO, followed by an open Q&amp;A session. The company will also discuss the outcomes of its recent Type B meeting with the U.S. Food and Drug Administration (FDA) regarding hidradenitis suppurativa, including next steps related to label strategy and the planned biologics license application submission.&nbsp;Additionally, the company plans to share an interim analysis of the continued response to SLK beyond Week 16 from the Phase 3 Vela trials in adult patients with hidradenitis suppurativa, as well as interim data from the Vela-Teen Phase 3 trial in adolescent patients.MoonLake said the Investor Day will also include an update on its financial position and a review of key 2026 catalysts. These include upcoming data releases from the Phase 3 Izar trials in psoriatic arthritis, as well as the planned Phase 3 development program in palmoplantar pustulosis.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MLTX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_34534e245f.webp" alt="mltx ss.png" width="961" height="144"><figcaption>MLTX sentiment and message volume as of February 22 | Source: Stocktwits</figcaption></figure>One user said, “I didn't think were were getting the financials until Wednesday. &nbsp; Looks very positive to me.&nbsp; Tomorrow should be epic, shorts might wanna cover ASAP.”<stembedurl>https://stocktwits.com/DerekVtx/message/645569026</stembedurl>Another user said, “Today had amazing news, tomorrow morning will have many announcements but there are many more to follow. This is like top 10 roadmaps for any drug company right now”&nbsp;<stembedurl>https://stocktwits.com/LouKojak/message/645565865</stembedurl>MLTX stock has risen 42% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown

 Investors are now turning to Monday’s Investor Day for regulatory clarity, pipeline updates, and key 2026 catalysts.

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given New $12.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada boosted their price target on shares of MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the stock a "sector perform" rating in a research note on Friday...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MLTX News

MLTXMoonLake Immunotherapeutics